Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence

Addictive Behaviors
John GrabowskiS Stevens Negus

Abstract

Stimulant abuse and dependence are disproportionately problematic due to the combination of legal and social issues added to the serious behavioural and biological features of the disorders. These problems are compounded by adverse consequences for families and society. Illegality and stigma multiply the consequences of use and difficulties in providing treatment. Specific behavioural interventions have been demonstrated as useful in treatment of substance use disorders (SUDs). Medications also have an important role in treatment. Effective agonist and antagonist pharmacotherapies as well as symptomatic treatments exist for opioid and nicotine dependence. Neither agonists nor antagonists have been approved as uniquely effective for treatment of stimulant abuse or dependence. Still, promising results are emerging for an agonist-like or 'replacement' strategy paralleling that for nicotine and opioid dependence. Supporting data have emerged from both preclinical and clinical research environments. There are scientific, clinical, social, and legal impediments to application of an agonist-like approach to stimulant abuse and dependence. Some resemble past and current concerns about opioid replacement. Others are unique to the stimul...Continue Reading

References

Oct 20, 1977·Psychopharmacology·B E Jones, J A Prada
Jul 1, 1991·Trends in Neurosciences·M J KuharJ W Boja
Jan 1, 1991·Journal of Substance Abuse Treatment·W S CondelliJ V Rachal
Jul 1, 1991·Scientific American·D F Musto
Sep 1, 1991·The American Journal of Psychiatry·S T HigginsJ W Fenwick
Apr 1, 1989·Archives of General Psychiatry·F H GawinB Humblestone
Nov 1, 1985·The American Journal of Psychiatry·E J Khantzian
Aug 1, 1985·The International Journal of the Addictions·D L StrugB Spunt
Jan 1, 1985·The American Journal of Drug and Alcohol Abuse·F GawinH Kleber
Oct 1, 1966·Archives of Internal Medicine·V P DoleM J Kreek
Nov 1, 1994·Addiction·H Pickering, G V Stimson
Jun 1, 1994·Journal of the Royal Society of Health·P M Fleming, D Roberts
Jul 11, 1994·Archives of Internal Medicine·T C Fagan
Mar 1, 1994·Archives of General Psychiatry·K M CarrollF H Gawin
Oct 1, 1995·Drug and Alcohol Dependence·E V NunesD F Klein
Jun 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·N K Mello, S S Negus
Jun 1, 1996·Drug and Alcohol Dependence·S L BatkiR T Jones
Dec 31, 1997·Journal of Clinical Psychopharmacology·J GrabowskiA Korszun
Jul 3, 1998·Drug and Alcohol Dependence·I PetrakisB Rounsaville
Jul 21, 1998·Annals of the New York Academy of Sciences·M Klein
Sep 19, 1998·The American Journal of Drug and Alcohol Abuse·F R LevinH D Kleber
Jul 30, 1999·Journal of Medicinal Chemistry·F I CarrollM J Kuhar
Feb 1, 2000·Journal of Clinical Psychopharmacology·J D RoacheH M Rhoades
Jun 1, 2000·Journal of Clinical Psychopharmacology·J GrabowskiR Bailey
Aug 25, 2000·Psychopharmacology·S L WalshG E Bigelow
Dec 21, 2000·Current Psychiatry Reports·G O'Leary, R D Weiss
Apr 24, 2001·Addictive Behaviors·J M SchmitzJ Grabowski
Jun 22, 2001·Drug and Alcohol Dependence·J M SchmitzJ Grabowski
Oct 11, 2001·Journal of Clinical Psychopharmacology·J GrabowskiF G Moeller
Jan 23, 2002·Vaccine·Thomas R KostenBarbara Fox

❮ Previous
Next ❯

Citations

Jun 10, 2010·Archives of General Psychiatry·Karen D ErscheTrevor W Robbins
Jul 2, 2005·Psychopharmacology·Sevil YasarJack Bergman
Feb 20, 2008·Psychopharmacology·Margaret Haney, Roger Spealman
Nov 23, 2010·Psychopharmacology·Karen D ErscheEdward T Bullmore
Mar 5, 2011·Psychopharmacology·Margaret HaneyRichard W Foltin
Jan 25, 2008·Applied Psychophysiology and Biofeedback·Tato M SokhadzeDavid L Trudeau
Sep 14, 2006·Current Psychiatry Reports·Walter LingWalter Ling
Sep 23, 2008·Current Psychiatry Reports·F Gerard MoellerKimberly L Kjome
Dec 18, 2008·Experimental and Clinical Psychopharmacology·William W Stoops
Dec 18, 2008·Experimental and Clinical Psychopharmacology·Richard B RothmanMichael H Baumann
Dec 18, 2008·Experimental and Clinical Psychopharmacology·Leonard L Howell
Oct 14, 2010·Experimental and Clinical Psychopharmacology·Jennifer L NewmanNancy K Mello
Feb 24, 2011·Experimental and Clinical Psychopharmacology·Charles W SchindlerSteven R Goldberg
Jul 17, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Clara Velázquez-SánchezJuan J Canales
Sep 10, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Xiao-Qing PengEliot L Gardner
Oct 1, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mark K GreenwaldCaren L Steinmiller
Oct 22, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paul W CzotyMichael A Nader
Oct 14, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gregory T CollinsJames H Woods
Mar 8, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mark J FerrisSara R Jones
Jun 6, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sandra D ComerRichard W Foltin
Aug 21, 2007·Journal of Psychoactive Drugs·Charles W MeredithAndrew J Saxon
Apr 28, 2006·Current Opinion in Psychiatry·Jane Carlisle Maxwell
Dec 16, 2010·Addiction Biology·Pia BäckströmPetri Hyytiä
Feb 27, 2009·The Journal of Pharmacology and Experimental Therapeutics·Richard B RothmanJohn S Partilla
Aug 28, 2009·The Journal of Pharmacology and Experimental Therapeutics·Gregory T CollinsJames H Woods
May 1, 2009·The Journal of Pharmacology and Experimental Therapeutics·Mark A SmithKatherine L Walker
Jan 14, 2011·The Journal of Pharmacology and Experimental Therapeutics·Michael H BaumannRichard B Rothman
Aug 23, 2011·The Journal of Pharmacology and Experimental Therapeutics·Robert W GouldMichael A Nader
Nov 7, 2013·The Journal of Pharmacology and Experimental Therapeutics·Takato HiranitaJonathan L Katz
Sep 2, 2009·Molecular Interventions·Meriem Gaval-Cruz, David Weinshenker
Sep 6, 2011·Molecular Pharmacology·Diwahar NarasimhanRoger K Sunahara
Dec 16, 2005·The AAPS Journal·Thomas E PrisinzanoWayne W Harding
Apr 6, 2007·The AAPS Journal·Richard B RothmanMichael H Baumann
Jun 4, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jane A Buxton, Naomi A Dove
Sep 14, 2007·CNS Drugs·Kevin P Hill, Mehmet Sofuoglu
Feb 4, 2012·Future Medicinal Chemistry·Craig R Rush, William W Stoops

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here